Skip to main content
. 2011 Dec 27;287(8):5327–5339. doi: 10.1074/jbc.M111.307009

FIGURE 4.

FIGURE 4.

Cat.G mediates c-Cbl activation through EGFR transactivation. A, NRCMs were pretreated with PP1 (10 μmol/liter) or AG1478 (10 μmol/liter) prior to treatment with Cat.G or EGF for 5 min. Cell lysates were assayed for phospho-c-Cbl-Y774, phospho-ERK1/2, c-Cbl and ERK1/2 immunoblot. Left: representative immunoblots. Right: quantification of experiments expressed as mean ± S.E. from three separate cultures. *, p < 0.05 versus control; #, p < 0.05 versus Cat.G or EGF-treated cells. B, c-Cbl immunoprecipitates from NRCMs treated with Cat.G or EGF for 5 min were immunoblotted with anti-EGFR, -phosphotyrosine (P-Tyr), -Src, or -c-Cbl antibodies. C and D, NRCMs were infected with Lac-Z, WT-EGFR, or EGFR-CD533 adenoviruses and then treated with Cat.G or EGF for 5 min (C) or 2 h (D). Left: representative immunoblots with GAPDH taken as loading control. Right: quantification of experiments expressed as mean ± S.E. from three separate cultures. *, p < 0.05 versus Lac-Z control, #, p < 0.05 versus Cat.G-treated cells.